<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00996749</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU 85108</org_study_id>
    <secondary_id>NCI-2009-01340</secondary_id>
    <nct_id>NCT00996749</nct_id>
  </id_info>
  <brief_title>Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer</brief_title>
  <official_title>Pilot Study to Determine the Optimal Dosage of Omega-3 Polyunsaturated Fatty Acid (PUFA) in Men With Advanced Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is studying the best way to give omega-3 fatty acids in treating patients
      with advanced prostate cancer. Omega-3 fatty acids may slow disease progression and may be an
      effective treatment for patients with advanced prostate cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. To conduct a pilot study of omega-3 polyunsaturated fatty acid (PUFA) (omega-3 fatty acid)
      supplementation in a group of patients with advanced prostate cancer to assess the dose of
      omega-3 PUFA necessary to achieve an omega-6 to -3 ratio of 1:1 on an individual basis and to
      assess the clinical impact of omega-3 supplementation on disease progression

      OUTLINE:

      Patients receive long-term omega-3 polyunsaturated fatty acid (PUFA) supplementation orally
      (PO).

      After completion of study treatment, patients are followed up at 1, 6, and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No Participants enrolled; slow accrual
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Omega-3 fatty acid levels in serum and fat biopsies</measure>
    <time_frame>At 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Omega-6 fatty acid levels in serum and fat biopsies</measure>
    <time_frame>At 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of omega-3 fatty acid supplementation</measure>
    <time_frame>At 1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of omega-3 fatty acid supplementation</measure>
    <time_frame>At 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of omega-3 fatty acid supplementation</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to PSA progression</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of PSA progression</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of bony metastasis</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density as assessed by dual energy x-ray absorptiometry (DEXA) scan</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density as assessed by DEXA scan</measure>
    <time_frame>At 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage III Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive long-term omega-3 PUFA supplementation PO.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 fatty acid</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
    <other_name>fish oil</other_name>
    <other_name>n-3 fatty acid</other_name>
    <other_name>O3FA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone scan</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dual x-ray absorptometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
    <other_name>DEXA scan</other_name>
    <other_name>dual energy x-ray absorptometry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (omega-3 fatty acid)</arm_group_label>
    <other_name>biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Disease is currently controlled with androgen ablation therapy Androgen ablation is
        expected to continue for at least 1 year Has been treated with androgen ablation therapy
        for at least 1 month Stable or decreasing prostate-specific antigen (PSA) on androgen
        ablation therapy Stable or no visible metastatic disease on imaging Eastern Cooperative
        Oncology Group (ECOG) functional status of at 0 or 1

        Exclusion Criteria:

        Eligible for local intervention with surgery or radiation Increasing serum PSA on hormonal
        ablation Radiographic evidence of progression of disease on hormonal ablation Current or
        history of second malignancy Previously treated with chemotherapeutic agents Previous
        history of intermittent androgen therapy Gastrointestinal (GI) disease that impacts
        absorption of nutrients
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Majid Mirzazadeh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2009</study_first_submitted>
  <study_first_submitted_qc>October 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2009</study_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

